Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
GLP-1 therapy uses medications that mimic or engage the GLP-1 incretin system to influence appetite, satiety, and glucose regulation
Mittag et al., 2010
Studies using human dermal papilla cells show that GHK-Cu increases proliferation, reduces caspase-3 (a key apoptosis enzyme) by roughly 43 percent, and upregulates growth factors including VEGF and basic fibroblast growth factor
Methylene Blue works by improving how cells use oxygen and produce energy
Its FDA-approved for diabetes and its potential weight-loss effects are currently being studied (7)
